alopecia

Posts

Stem Cell Alopecia Treatment Market

Global Platelet Rich Plasma

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2021

The research report includes specific segments by region (country), by company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027.

Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Segment by Application

Hospital
Dermatology Clinic
Other

By Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company

Kerastem
Eclipse
Regen Lab SA
Stemcell Technologies
RepliCel Life Sciences
Histogen
Glofinn Oy.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2021

Source

Recent Posts

Stem Cell Alopecia Treatment Market

Global Platelet Rich Plasma

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2021

The research report includes specific segments by region (country), by company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027.

Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Segment by Application

Hospital
Dermatology Clinic
Other

By Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company

Kerastem
Eclipse
Regen Lab SA
Stemcell Technologies
RepliCel Life Sciences
Histogen
Glofinn Oy.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2021

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Market Scenario Globally

Global Statistics Representing Alopecia Market Scenario Globally

Globally, the prevalence of alopecia, such as androgenetic alopecia and alopecia areata, is increasing at a concerning rate. This can be attributed to the rising consumption of unhealthy food, sedentary lifestyle, genetic factors, hormonal imbalance, rising healthcare expenditure, increasing chronic diseases, surging geriatric population, rising disposable incomes, and high focus on aesthetic appearance.

As per the American Hair Loss Association, globally, around 95% of men face hair loss, and over 8, 00,000 people seek treatment for the same. For the record, alopecia is also common in women, and about one-third of women are suffering from androgenetic alopecia across the globe.

Moreover, women suffering from postmenopausal and Polycystic Ovary Syndrome (PCOS) are more likely to develop hair thinning and bald spots adoption of surgical hair transplant and scalp treatments. To attend to the situation, several leading players are actively working to develop novel therapeutic drugs and are heavily investing in R&D activities for the same. For instance, the introduction of fast-acting JAK inhibitors, and PRP treatment is driving the market growth.

Segmental Insights

The global alopecia market is segmented into disease type, end-user, sales channels, and gender.

Alopecia Areata to Witness Significant Growth

By disease type, the alopecia market is further segmented into cicatricial alopecia, alopecia totalis, areata, androgenetic alopecia, Universalis, and among others. The alopecia areata segment is expected to witness significant growth during the forecast period on account of the surging prevalence of a number of diseases, such as diabetes, hyperthyroidism, and Down’s syndrome. Moreover, alopecia totalis and Universalis are the advanced stages of alopecia areata.

The androgenetic alopecia is the fastest-growing segment. It is majorly driven by the launch of pipeline drugs and the increasing prevalence of diseases. It is majorly caused among the individuals associated with a genetic predisposition to hair loss. To attend to the situation, a number of treatment options have been developed by the leading players, including finasteride and minoxidil, licensed topical treatment, and surgical treatment like hair transplant.

Dermatology Clinics to Dominate the Market

By the end-user, the alopecia market is segmented into dermatology, clinics, home care settings, and others.

The dermatology clinics segment is dominating the alopecia market and will continue the same during the forecast period. This can be attributed to the rising number of hair restoration and transplantation surgeries across the globe. The clinic segment is expected to hold a significant share in the market on account of the rising availability of technologically advanced therapies, robust healthcare infrastructure, and growing demand for single session hair restoration procedures across the globe. On 13th May 2019, Bosley and Hair Club announced the launch of BioGraft. The groundbreaking treatment incorporates both surgical and non-surgical hair restoration for rapid transformation and is now available to patients across the globe.

The home care settings segment is majorly driven by the rising number of regulatory approvals for home-use devices, increasing adoption of laser therapy for hair loss treatment, technological advancements, and availability of innovative devices. The laser combs segment is grabbing the highest shares in the home care setting segment as it reduces pain, aids in fast healing, remove the blockage, improves blood circulation, ensures oxygen supply to the scalp, aids in cell replacement, and increases the strength, shine, and elasticity of hair.

Over the Counter Products to Lead the Market

By sales channel, the alopecia market is bifurcated into prescription-based and over the counter (OTC) products. The over the counter products segment is leading the alopecia market. This can be accredited to the growing demand for low-cost treatment and the availability of alternatives. Additionally, a surge in the number of FDA approval for OTC hair loss treatment products is adding fuel to the market growth. For instance, recently, the FDA approved ‘Keranique’ hair regrowth serum and ‘Oscar Blandi hair lift’ serum for instant thickening and strengthening of hair.

By Gender, Alopecia to be More Prevalent in Men than Women

As per the American Hair Loss Association and the U.S. National Library of Medicine, around 50% of men experience hair fall at the age of 50. Moreover, the surge in the geriatric population and high tobacco intake among men is driving the market growth. For the record, some men also experience hair loss in the teens and early twenties due to fluctuating hormones. Whereas, around 40% of the women experience hair loss at the age of 50. Women with menopause are more likely to suffer from hair loss due to a drop in hormone levels. However, alopecia is not permanent in women and can be caused due to stress.

Regional Insights

North America to Dominate the Alopecia Market

North America is dominating the alopecia market on account of increasing advancements in the healthcare infrastructure, availability of novel therapeutics treatment options, rising healthcare expenditure, and high disposable income. As per the U.S. National Library Health Medicine, 1 out of 1000 Americans suffers from alopecia. According to IMS Health, currently, there are around 9,600 dermatologists and about 7,800 dermatology clinics across the U.S. that are arduously working to attend to the situation.

Asia Pacific to be the Fastest Growing Market

Asia Pacific is the fastest growing alopecia market and is expected to grow at a CAGR of 6.9% during the forecast period. This can be attributed to the availability of advanced treatment options and increasing spending power in emerging economies, such as Singapore, India, and China. Moreover, the consumer base in the region prefers traditional alopecia therapy, which includes oil massage and hair masks. In South Korea, China, Japan, and India, the aesthetic drugs are witnessing huge popularity and are anticipated to drive the market growth to some extent.  Other factors driving the market include the rising prevalence of alopecia areata and several skin-related disorders, increasing population, rising incidence of chronic diseases, and changing lifestyle.

South America

South America’s alopecia market is anticipated to reach USD 34.7 million by 2023. Argentina is the fastest growing market in South America on account of the rising geriatric population and sedentary lifestyle. The country is also adopting hair loss treatment and has surpassed a volume of around 52,000 hair loss treatment products in 2017. The region is backed by the presence of leading players that are actively working in the field to sustain in the raging competition. Currently, the players are focusing on developing herbal and natural ingredients to promote hair growth. Furthermore, Brazil is expected to witness significant growth during the forecast period. This can be attributed to the increasing demand for hair care products containing both active and medicinal ingredients.

The Middle East and Africa to Offer Significant Opportunities in the Coming Years

The Middle East and Africa will offer lucrative growth opportunities in the alopecia market during the forecast period owing to increasing technological advancements, rising healthcare expenditures, growing support by the government, and advancement in healthcare facilities.

Competitive Landscape: Market Moving Towards Consolidation

The global alopecia market is highly fragmented in nature, with different market players operating in local regions. Some of the key players are engaging in acquisitions, collaborations, and partnerships to gain a competitive edge. For instance, Johnson & Johnson Consumer, Inc. collaborated with the University of Pennsylvania to design improved preclinical models for the study of human hair growth and androgenetic alopecia. On 6th July 2016,  Alpecin has expanded its footprint in the China market. The alopecia market is consolidated with the presence of Kirkland Signature Vitabiotics, Sun Pharma, Merck & Co., Dr. Reddy’s Laboratories, Cipla, Johnson & Johnson, Alpecin, Phyto Ales Group, and Lifes2good.

Alopecia Market Segmentation

By Disease Type

  • Cicatricial Alopecia
  • Alopecia Totalis
  • Areata
  • Androgenetic Alopecia
  • Universalis
  • Others

By End-User

  • Dermatology
  • Clinics
  • Homecare Settings
  • Others

By Sales Channels

  • Prescription-Based
  • Over the Counter (OTC) Products

By Region

  • Americas
  • Europe
  • AsiaPacific
  • MEA

Global Statistics Representing Alopecia Market Scenario Globally

Source

Recent Posts

Hair Regrowth in Phase 3 Alopecia Areata

Hair Regrowth in Phase 3 Alopecia Areata

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Eli Lilly and Company announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA).

Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.

Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint(s). There are currently no FDA-approved treatments for AA.

“These positive results are very promising and suggest that baricitinib has the potential to address the urgent needs of people living with alopecia areata,” said Brett King, M.D., Ph.D., associate professor of Dermatology at Yale School of Medicine. “This level of high-quality research is needed to advance our understanding and the treatment of this frequently devastating disease.”

This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool (SALT) score ≥ 50 (i.e., who had ≥50% scalp hair loss) and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S.

Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis (RA) and atopic dermatitis (AD). No deaths, major adverse cardiovascular events (MACE) or venous thromboembolic events (VTEs) were reported in the study.

BRAVE-AA2 is the first Phase 3 study with positive results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD.

“For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects. They lose much more than just hair,” said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. “We are looking forward to sharing the totality of data from the overall clinical development program for baricitinib as a potential first-in-disease treatment for alopecia areata.”

“Significant unmet need exists in the treatment of alopecia areata,” said Abby Ellison, research director at the National Alopecia Areata Foundation (NAAF). “We appreciate Lilly’s important work in this area and are excited that these data could bring us closer to a potential new treatment option for patients.”

Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as OLUMIANT in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA) and COVID-19.

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

The Alopecia Treatment market is expected to grow in the future due to a rising R&D activity to improve treatment options and accelerated regulatory approvals.

There are five major kinds of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium.

The rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Growth Drivers

  • Surge in Geriatric Population
  • Rise in Prevalence of Alopecia Conditions such as Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others
  • Increase in Prevalence of Chemotherapy-Induced Alopecia

Market Trends

  • Technological Advancements and the Development of Novel Therapeutic Drugs

Roadblocks

  • Lack of Reimbursement Policies
  • High Cost of Medications

Opportunities

  • Surge in Patient Awareness Regarding the Alopecia Totalis Disorder
  • Large Presence of Pharmaceutical Companies

Challenges

  • Side Effects, Reactions, and Allergies Caused by Alopecia Treatments

Competitive Landscape:

The global Alopecia Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.

Some of the key players profiled in the report are Johnson & JohnsonServices, Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Cipla Inc. (India), Lexington International LLC (United States), Merck & Co., Inc. (United States), Vita-Cos-Med Klett-Loch GmbH (Germany), Cirrus Hair Centers (United States), Transitions Hair Pty Ltd. (United States), Capillus (United States) and Follica, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Alopecia Treatment market by 2025.

Considering Market by Drug, the sub-segment i.e. Minoxidil will boost the Alopecia Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Prescriptions will boost the Alopecia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Alopecia Treatment market.

Latest Market Insights:

In Mar 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body.

In June 2020, Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019., and In Oct 2020, Histogen Inc. announced the completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability, and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Market Analysis and Insights of Global Alopecia Treatment (Hair Loss) Market

Alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the alopecia treatment (hair loss) market to account to USD 5,461.35 million by 2028 growing at a CAGR of 6.0% in the above-mentioned forecast period.

Rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) has been directly impacting the growth of alopecia treatment (hair loss) market.

Alopecia is a condition that causes hair to fall out in small patches, which can be unnoticeable. These patches may connect, however, and then become noticeable. The condition develops when the immune system attacks the hair follicles, resulting in hair loss.

The increasing need for an effective treatment for alopecia (hair loss) is the main driving factor for the alopecia treatment (hair loss) market. Rising pharmaceutical industries and various research & clinical studies are driving the alopecia treatment (hair loss) market. Various innovative clinical programmes is an opportunity for the alopecia treatment (hair loss) market.

Lack of awareness in rural countries is a big challenge for the alopecia treatment (hair loss) market. However, the high cost of treatment is the main restraint in the growth of alopecia treatment (hair loss) market during the forecast period of 2021-2028.

This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to improve the sales of its product which is Rogaine, a hair loss treatment including minoxidil. JW Pharmaceutical has signed a distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This lead enabled the company to gain more product sales which have increased the company’s overall revenue.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

Alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with a valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on disease type, the alopecia treatment (hair loss) market is segmented into non‒cicatricial alopecia, cicatricial alopecia, traction alopecia and others.
  • Based on treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment.
  • Based on gender, the alopecia treatment (hair loss) market is segmented into male and female.
  • Based on form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral.
  • Based on end-user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centres.
  • Based distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies.

Alopecia Treatment (Hair Loss) Market Country Level Analysis

Alopecia treatment (hair loss) market is segmented into is analysed and market size insights and trends are provided by country, disease type, treatment, gender, form, end-user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market is segmented into the report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is likely to lead the alopecia treatment (hair loss) market. The regional market has been driven by a common form of alopecia and people with alopecia aerate affects. However, the growing market with new players is the main factor propelling the growth of the regional market. The market in Asia-Pacific is expected to exhibit a substantial growth rate during the forecast period 2021-2028 due to the rise in prevalence of alopecia and rising usage of hair care therapies for the treatment.

The country section of the alopecia treatment (hair loss) market is segmented into report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import-export analysis, price trend analysis, cost of raw materials, downstream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for alopecia treatment (hair loss) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the alopecia treatment (hair loss) market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to alopecia treatment (hair loss) market.

The major players covered in the alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Par Pharmaceutical, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Aurobindo Pharma, Perrigo Company plc, Viviscal Limited, Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech are among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Market Analysis

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth.

According to the National Center for Biotechnology Information (NCBI), in August 2015, the global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel the growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting a clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females.

The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

Report Coverage Details

Base Year:
2019

Market Size in 2020:
US$ 1,607.47 Mn

Historical Data for:
2016 to 2019

Forecast Period:
2020 to 2027

Forecast Period 2020 to 2027 CAGR:
5.3%

2027 Value Projection:
US$ 2,298.34 Mn

Geographies covered:

  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa

Segments covered:

  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:

  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia

Restraints & Challenges:

  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit the growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic Alopecia Treatment Market Analysis

Source

Recent Posts

Alopecia Treatment Market

Global Alopecia Drugs Market Report

Global Alopecia Drugs Market Report

The Alopecia Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Alopecia Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Alopecia Drugs market.

The report focuses on well-known providers in the global Alopecia Drugs industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Alopecia Drugs Industry will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Key players in the global Alopecia Drugs market covered in Chapter 4

Dr. Reddy’s Laboratories Ltd
Cipla Inc.
Aqua Pharmaceuticals
Bayer HealthCare
Merck
Helix BioMedix
The Himalaya Drug Company
GlaxoSmithKline
Johnson & Johnson
AndroScience

In Chapter 11 and 13.3, on the basis of types, the Alopecia Drugs market from 2015 to 2026 is primarily split into:_x000D_

Oral
Topical
Injectable

In Chapter 12 and 13.4, on the basis of applications, the Alopecia Drugs market from 2015 to 2026 covers:

Men
Women

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

Global Alopecia Drugs Market Report

Source

Recent Posts

Alopecia Treatment Market

Alopecia Market Size

Alopecia Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region – Global Forecast To 2025

Up Market Research offers a latest published report on “Global Global Alopecia Market Research Report 2019 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Global Alopecia Market Research Report 2019 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.

It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Global Alopecia Market Research Report 2019 Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2019 – 2026.

The report for Global Alopecia Market Research Report 2019 Market analysis & forecast 2019 – 2026 is segmented into Product Segment, Application Segment & Major players.

Region-wise Analysis Global Alopecia Market Research Report 2019 Market covers:

• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The Global Alopecia Market Research Report 2019 Market Report can be segmented into Product Types and Applications.

The Report Covers In-Depth Analysis As Follows:

• Chapter 1 Overview of Global Alopecia Market Research Report 2019 Market
• Chapter 2 Global Market Status and Forecast by Regions
• Chapter 3 Global Market Status and Forecast by Types
• Chapter 4 Global Market Status and Forecast by Downstream Industry
• Chapter 5 Market Driving Factor Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 6 Global Alopecia Market Research Report 2019 Market Competition Status by Major Manufacturers
• Chapter 7 Global Alopecia Market Research Report 2019 Market Major Manufacturers Introduction and Market Data
• Chapter 8 Upstream and Downstream Market Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 9 Cost and Gross Margin Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 10 Marketing Status Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 11 Report Conclusion
• Chapter 12 Research Methodology and Reference

“Global Alopecia Market Research Report 2019 Market Analysis and Forecast 2019 – 2026” report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market-driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-time scenario.

Global Alopecia Market Research Report 2019 Market: Key Stakeholders:

• Manufacturers
• Distributors/Traders/Wholesalers
• Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

In this study, the years considered to estimate the market size of the Global Alopecia Market Research Report 2019 Market are as follows:

• History Year: 2013-2018
• Base Year: 2018
• Estimated Year: 2019
• Forecast Year 2019 to 2026

Key Reasons to Purchase:

• To gain insightful analyses of the market and have a comprehensive understanding of the “Global Alopecia Market Research Report 2019 Market” and its commercial landscape.
• Learn about the market strategies that are being adopted by your competitors and leading organizations.
• To understand the future outlook and prospects for Global Alopecia Market Research Report 2019 Market analysis and forecast 2019 – 2026.

Customization of the Report:

Up Market Research provides free customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

You can also ask for region wise market research report, as below:

• Global Alopecia Market Research Report 2019 Market – Global Market Status & Trend Report 2013- 2026 Top 20 Countries Data
• Global Alopecia Market Research Report 2019 Market – North America Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – South America Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – Europe Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – EMEA Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – Asia Pacific Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – China Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – India Market Status and Trend Report 2013- 2026

Alopecia Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region – Global Forecast To 2025

Recent Posts

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Alopecia Areata

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020.

The oral presentation will highlight new data from an ongoing open-label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
  • Session: D1T03.3C: Late-Breaking News Session
  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com

1 Benigno M. Clinical, Cosmetic and Investigational Dermatology 2020

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Source

Previous Post

Alopecia Treatment Market

Global Alopecia Market

Global Alopecia Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025

Eon Market Research has added a report titled “Global Alopecia (Hair Loss Treatment) Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025”. The report will include the impact of COVID 19 and its impact on the growth of this industry during the forecast period.

The Alopecia (Hair Loss Treatment) market report offers the growth scenarios present globally as well as revenues of the overall market. The Global Alopecia (Hair Loss Treatment) market report thoroughly discusses robust growth prospects and prominent strategies implicated by several key players operating in the global market, which are likely to benefit the market growth and grab a leading position in terms of revenue in the Alopecia (Hair Loss Treatment) market.

In this report, the global Alopecia (Hair Loss Treatment) market is estimated at USD XX million in 2020 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2020 and 2025.

Geographically, this report is segmented into various key Regions

North America
Europe
China
Japan
Southeast Asia
India

Global Alopecia (Hair Loss Treatment) market competition

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter and Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Based on product

Shampoos and Conditioners
Medicine Product

Based on the end users/applications

Men
Women

Global Alopecia Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025

Source

Previous Post